{"id":35368,"date":"2024-04-02T13:16:25","date_gmt":"2024-04-02T11:16:25","guid":{"rendered":"https:\/\/www.abcsg.org\/?page_id=35368"},"modified":"2025-03-11T16:32:14","modified_gmt":"2025-03-11T15:32:14","slug":"abcsg-62-cambria-2-overview","status":"publish","type":"page","link":"https:\/\/www.abcsg.org\/en\/abcsg-studien\/studies-open-for-enrollment\/abcsg-62-cambria-2-2\/abcsg-62-cambria-2-overview\/","title":{"rendered":"ABCSG 62 \/ CAMBRIA-2 Overview"},"content":{"rendered":"<p>A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+\/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease.<\/p>\n<table>\n<tbody>\n<tr>\n<td><b>Start:<\/b><\/td>\n<td>(global): 10\/2023; FPI 10\/2023<br \/>\n(national): 04\/2024<\/td>\n<\/tr>\n<tr>\n<td><b>Coordinating Investigator AT:<\/b><\/td>\n<td>Daniel Egle, Innsbruck<\/td>\n<\/tr>\n<tr>\n<td><b>Sample:<\/b><\/td>\n<td>5500 (global),<br \/>\n128 (national)<\/td>\n<\/tr>\n<tr>\n<td><b>Study design:<br \/>\n<\/b><i>(Click to enlarge)<\/i><\/td>\n<td><a  href=\"https:\/\/www.abcsg.org\/wp\/wp-content\/uploads\/2024\/04\/ABCSG-62.jpg\" data-rel=\"lightbox-gallery-0\" data-rl_title=\"\" data-rl_caption=\"\" title=\"\"><img decoding=\"async\" class=\"alignnone wp-image-35359 size-full\" src=\"https:\/\/www.abcsg.org\/wp\/wp-content\/uploads\/2024\/04\/ABCSG-62.jpg\" alt=\"ABCSG 62\" width=\"280\" srcset=\"https:\/\/www.abcsg.org\/wp\/wp-content\/uploads\/2024\/04\/ABCSG-62.jpg 1178w, https:\/\/www.abcsg.org\/wp\/wp-content\/uploads\/2024\/04\/ABCSG-62-280x104.jpg 280w, https:\/\/www.abcsg.org\/wp\/wp-content\/uploads\/2024\/04\/ABCSG-62-768x286.jpg 768w\" sizes=\"(max-width: 1178px) 100vw, 1178px\" \/><\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+\/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":35334,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-einzel-studie.php","meta":{"_acf_changed":false,"footnotes":""},"tags":[],"class_list":["post-35368","page","type-page","status-publish","hentry"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-11-29 18:36:28","action":"delete","newStatus":"draft","terms":[],"taxonomy":"translation_priority","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages\/35368","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/comments?post=35368"}],"version-history":[{"count":4,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages\/35368\/revisions"}],"predecessor-version":[{"id":38018,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages\/35368\/revisions\/38018"}],"up":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages\/35334"}],"wp:attachment":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/media?parent=35368"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/tags?post=35368"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}